Pharmacyclics, Inc.  

(Public, NASDAQ:PCYC)   Watch this stock  
Find more results for PCYC
96.71
-0.45 (-0.46%)
Real-time:   9:56AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 95.57 - 97.50
52 week 82.51 - 154.89
Open 97.08
Vol / Avg. 16,186.00/1.14M
Mkt cap 7.26B
P/E 54.95
Div/yield     -
EPS 1.76
Shares 75.03M
Beta 0.72
Inst. own 71%
Jul 28, 2014
Q2 2014 Pharmacyclics Inc. Earnings Release (Estimated) Add to calendar
Jun 24, 2014
Pharmacyclics Inc at JMP Securities Healthcare Conference
May 8, 2014
Pharmacyclics Inc. Annual Shareholder Meeting
May 7, 2014
Pharmacyclics Inc. at Deutsche Bank Healthcare Conference
May 2, 2014
Q1 2014 Pharmacyclics Inc. Earnings Release
May 2, 2014
Q1 2014 Pharmacyclics Inc. Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 15.31% 25.76%
Operating margin 15.27% 37.64%
EBITD margin - 38.49%
Return on average assets 9.31% 11.92%
Return on average equity 11.35% 15.06%
Employees 484 -
CDP Score - -

Address

995 E ARQUES AVE
SUNNYVALE, CA 94085-4521
United States - Map
+1-408-7740330 (Phone)
+1-408-7740340 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�s tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

Officers and directors

Robert W. Duggan Chairman of the Board, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Manmeet Soni Chief Financial Officer, Executive Vice President - Finance, Chief Accounting Officer, Treasurer
Age: 36
Bio & Compensation  - Reuters
Mahkam Zanganeh DDS Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
Rainer M. Erdtmann Senior Vice President - Investor Relations and Administration
Age: 50
Bio & Compensation  - Reuters
Urte Gayko Ph.D. Senior Vice President - Regulatory
Age: 42
Bio & Compensation  - Reuters
Sumita Ray Chief Compliance Officer, Associate General Counsel - Healthcare Law
Bio & Compensation  - Reuters
Gregory W. Hemmi Ph.D. Vice President - Chemical Operations
Age: 47
Bio & Compensation  - Reuters
Darrin Beaupre MD, PhD. Vice President - Clinical Medicine and Early Development
Bio & Compensation  - Reuters
Betty Y. Chang Ph.D. Vice President - Research/Biology
Bio & Compensation  - Reuters
Fong Wang Clow Vice President - Biostatistics, Programming, and Data Management
Age: 55
Bio & Compensation  - Reuters